左卡尼汀联合金水宝治疗维持性血液透析慢性肾功能衰竭患者的临床效果观察

目的:观察左卡尼汀联合金水宝治疗维持性血液透析慢性肾功能衰竭患者的临床效果.方法:选择2018年6月至2021年2月在重庆医科大学附属永川医院行维持性血液透析的慢性肾功能衰竭患者92例,随机分为治疗组(n=46)和对照组(n=46).对照组采用左卡尼汀治疗,治疗组在对照组基础上联合金水宝治疗.比较两组临床疗效以及血清中...

Clinical efficacy of levocarnitine combined with Jinshuibao in the treatment of patients with chronic renal failure undergoing maintenance hemodialysis

Objective: To evaluate the clinical effect of levocarnitine combined with Jinshuibao on patients with chronic renal failure patients undergoing maintenance hemodialysis. Methods:  Ninety two patients with chronic renal failure who underwent maintenance hemodialysis in Yongchuan Hospital Affiliated to Chongqing Medical University from June 2018 to February 2021 were selected in the study, and were randomly divided into the treatment group (n=46) and the control group (n=46). The control group was treated with levocarnitine, and the treatment group was treated with Jinshuibao on the basis of the control group. Clinical efficacy and level of inflammatory factors, matrix metalloproteinases, nutritional indicators, stromal cell-derived factor-1 (SDF-1), vitamin D and vitamin B12 in serum were compared between the two groups. Results:After treatment, the total clinical effective rate of treatment group (89.13%) was significantly higher than that of control group (69.57%, P<0.05). After treatment, the levels of tumor necrosis factor-α(TNF-α), IL-6, C-reactive protein (CRP), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and SDF-1 in 2 groups were significantly decreased compared with before treatment(all P<0.05). The levels of total protein, albumin, hemoglobin, vitamin D and vitamin B12 were higher than those before treatment(all P<0.05); and the contents of TNF-α, IL-6, CRP, MMP-2, MMP-9 and SDF-1 in treatment group were lower than those in control group (P<0.05), and the levels of total protein, albumin, hemoglobin, vitamin D and vitamin B12 in treatment group were higher than those in control group(P<0.05). There was no significant difference in the incidence of adverse reactions and complication between the two groups(both P＞0.05). Conclusion:  Levocarnitine combined with Jinshuibao could improve the clinical efficacy, reduce micro inflammatory reaction, improve nutritional status in patients with chronic renal failure undergoing maintenance hemodialysis.